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Abstract 
Leber’s hereditary optic neuropathy (LHON) is currently estimated as the most frequent 
mitochondrial disease (1 in 27,000-45,000). Its molecular pathogenesis and natural history is now 
fairly well understood. Furthermore, LHON is also the first mitochondrial disease for which a 
therapy has been approved (based on the antioxidant drug idebenone - Raxone®, Santhera 
Pharmaceuticals) in June 2015 by the European Medicine Agency (EMA), under exceptional 
circumstances due to the rarity and severity of the disease. However, what remains unclear 
includes the optimal target population, timing, dose and frequency of administration of idebenone 
in LHON due to lack of accepted definitions, criteria and general guidelines for the clinical 
management of this mitochondrial disorder. To address these issues, a consensus conference with 
a panel of experts from Europe and North America was held in Milan (Italy) in 2016. The 
conference aimed at providing expert consensus statements for the clinical and therapeutic 
management of LHON based on the currently available evidence, and this report presents the 
conclusions of this conference, providing the first guidelines ever for clinical and therapeutic 
management of LHON. 
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Introduction 
Leber’s hereditary optic neuropathy (LHON) is a paradigm for mitochondrial diseases in 
many regards. It was the first disease to be associated with mitochondrial DNA (mtDNA) point 
mutations (1), and is hence maternally inherited.  These mutations affect complex I subunit genes. 
LHON is the most frequent mitochondrial disorder with a prevalence ranging from 1 in 27,000 in 
North-East of England (2), to 1 in 45,000 in a meta-analysis of reports on the European population 
(3).  
LHON is a blinding disorder, usually affecting young men and leading to selective 
degeneration of retinal ganglion cells (RGCs) and optic atrophy within a year after disease onset.  
The subset of macular RGCs, providing axons for the papillomacular bundle and serving central 
vision, are affected first and preferentially, resulting in loss of visual acuity, dyschromatopsia, large 
central scotomas, and temporal pallor of the optic disc (4,5). Recent optical coherence 
tomography (OCT) and histopathology studies have substantiated the occurrence of a precise 
pattern in retinal nerve fiber layer (RNFL) loss, disease progression and natural history (6,7). In 
particular, loss of macular RGCs precedes the clinical disease onset; by approximately four months, 
maximal loss has occurred (8).  
In unaffected carriers of the LHON mutation there may be recognizable changes on fundus 
examination and OCT measurements including vascular abnormalities (microangiopathy and 
telangectatic vessels), hyperemia of the optic disc, and fiber swelling (pseudoedema) that is 
objectively detected by OCT as increased thickness of the retinal fiber layer at the inferior and 
temporal quadrants (9,10). The conversion to the symptomatic stage is characterized by loss of 
macular RGCs on OCT (preclinical changes), but with visual acuity and fields still being normal (8). 
A central scotoma subsequently develops and central visual acuity starts to deteriorate rapidly, at 
which stage the patient usually seeks medical attention. The evolution in the first weeks/months is 
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described canonically as acute/subacute, depending on how rapidly the loss of central vision 
evolves (11). Within four to six months visual acuity stabilizes, but clinical metrics such as visual 
fields and OCT measurements may still evolve, usually plateauing at one year after onset. At this 
point, the so-called acute phase ends with a transition into the chronic stage of the disease. 
Despite the fact that most patients remain stable for the rest of their lives with profoundly 
impaired vision, a subgroup may experience some degree of spontaneous visual recovery 
depending on the mutation subtype and the age at onset (12). This usually manifests as a shrinking 
and/or a fenestration of the scotoma.  
LHON is primarily a clinical diagnosis.  The features common to all mitochondrial optic 
neuropathies consist of central or cecocentral scotomas, impaired color vision and ultimately optic 
nerve head pallor, especially temporally.  In this context, particularly in a young adult, a subacute 
onset and a maternal family history of visual loss can be very useful in determining the diagnosis.  
A definitive diagnosis of LHON is currently rapidly obtained by the molecular identification of one 
of the three common mtDNA mutations (m.11778G>A/MT-ND4, m.3460G>A/MT-ND1, 
m.14484T>C/MT-ND6), accounting for about 90% of cases. If this primary screen is negative and 
there is a high index of clinical suspicion supported by a maternal mode of inheritance in a patient 
with a family history, sequencing the entire mtDNA is advisable to identify one of the rare LHON 
mutations (13).  
The literature frequently states that there is no proven therapy for LHON despite many 
purported treatments being tested (14,15). However, the European Medicine Agency (EMA) 
approved in June 2015, under exceptional circumstances due to the rarity and severity of the 
disease, the use of idebenone (Raxone®, Santhera Pharmaceuticals) in LHON, recognizing a 
sufficient amount of clinical evidence for safety and partial efficacy in a subgroup of treated 
patients (16-20). The approved product label states that idebenone is indicated for the treatment 
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of visual impairment in adolescents and adult patients with LHON at a dose of 900mg per day in 3 
divided doses. However, there remains some controversy on the optimal target population, 
timing, dose and frequency of administration of idebenone in LHON patients, compounded by the 
lack of accepted definitions, criteria and general guidelines for the clinical management of this 
mitochondrial disorder.  
To address these issues, a consensus conference with a panel of experts from Europe and 
North America was held in Milan (Italy). The conference aimed at providing expert consensus 
statements for the clinical and therapeutic management of LHON based on the currently available 
evidence.  
 
Methods 
In March 2016 (18th-19th) there was an inaugural congress, “Update on Optic Nerve 
Degeneration - a European network:  1st international meeting “, held in Milan, Italy under the 
patronage of the San Raffaele Scientific Institute, a tertiary reference health care center in 
Northern Italy. There were approximately 200 attendees and this provided the opportunity for 
gathering most of the world experts in mitochondrial optic neuropathies. A satellite meeting 
“Consensus Conference” focused on the “Clinical and Therapeutic management of LHON” was 
promoted and hosted by the San Raffaele Institute with technical and secretarial support provided 
by a private and independent editorial and journalistic consultancy agency – Content Ed 
(www.contentednet.com). 
The expert panel consisted of 16 leading investigators in the field from Europe and North 
America who were chosen on the basis of their international recognition as experts in 
mitochondrial optic neuropathies and in particular in LHON and contacted six months in advance. 
Carelli et al., Consensus on LHON 2016 7 
The final consensus jury included 13 experts, neurologists and ophthalmologists, who accepted to 
participate and were able to attend in person. Three additional experts (AK, CC-V and MV) did not 
attend in person the consensus conference, but contributed substantially to different phases of 
the process. All participants were clinicians and investigators who had extensive experience in 
clinical and genetic management and research, as well as treatment of optic neuropathies and 
LHON. Three scientific participants (VC, PB and CLM) were appointed to lead the consensus 
process serving as the scientific committee. They also participated in the voting sessions due to 
the limited number of LHON experts and their widely recognized expertise in the field. The 
consensus process was conducted in line with the last updated methodological indications of the 
Italian Institute of Health (21). It was developed in 4 stages:   
1. Development of clinically relevant questions on LHON and definition of preliminary statements 
on the basis of a non-systematic literature review,  
2. Integration of the feedback from the components of the jury,  
3. Consensus meeting with discussion and voting of refined statements on the basis of 
participants’ clinical experience and available evidence,  
4. Analysis and publication of the final consensus statements. 
The scientific committee identified a number of clinically relevant questions about LHON 
suitable for consensus discussion and formulated a series of statements addressing each question 
according to their experience and clinical evidence. All relevant scientiﬁc literature, as identiﬁed 
by scientific leaders and two methodological experts, was reviewed in advance in order to identify 
questions and draft preliminary statements relating to each question. To this end, a literature 
search was undertaken and was last updated on 15th March 2016. The data pack included studies 
relevant for the questionnaire topics, as identified by a MEDLINE search using “Leber’s Hereditary 
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Optic Neuropathy” or “Leber Hereditary Optic Neuropathy” or “LHON” as query, with no 
restrictions on publication date, but only studies published in English were considered. Studies 
were selected for inclusion if they were: (a) randomized, double-blind, placebo-controlled, or 
uncontrolled trials; (b) observational studies including prospective or retrospective cohort studies, 
case-control or cross sectional studies; (c) case series; (d) case reports; (e) systematic reviews and 
meta-analyses; (f) expert opinion-based pieces; and (f) guidelines. 673 papers were identified and 
made available to all participants, representing the basis for the proposed statements (listed in 
Supplementary Materials). 
Before the meeting, all members of the jury received the questions and the statements 
elaborated by scientific leaders, for their assessment and possible changes. All changes and 
suggestions were considered by the three scientific leaders and the statements were then 
consolidated in a version that served as the basis for the discussion at the consensus meeting 
covering four main topics in LHON: (I) Staging; (II) Diagnosis and prognosis; (III) Therapeutic 
management; (IV) Screening family members; with a total of 20 questions.  
The meeting, on March 17th at San Raffaele Scientific Institute in Milan, lasted 7 hours 
during which the scientific leaders presented each of the questions/statements. Each statement 
was debated, reformulated when it was considered incorrectly posed or misleading and then 
voted through a 4-point Likert-type scale handled by an electronic voting system (“1 - completely 
disagree”, “2” partially disagree”, “3” partially agree”, “4” completely agree”). The total maximum 
possible score for any given statement was then 52 (in the case all 13 voters completely agreed to 
the proposed statement allocating a score of 13×4). The “consensus” threshold was set at ≥60% of 
the total possible score, whilst the “stronghigh consensus” threshold was set at ≥75%. Each 
participant (including scientific leaders) was equally weighted in scoring the statements. If one of 
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these two thresholds was met, the statement was considered approved. If a consensus was not 
reached (i.e. a score of < 60%), the statement was considered not approved.  
The results that were originally tabulated at the consensus meeting were submitted in 
Microsoft PowerPointTM form to all members of jury, for their final approval. The manuscript 
reporting the outcomes of the consensus conference was drafted by the scientific leaders and 
circulated to all members of the jury for final editorial additions and approvals. 
 
ResultsThe statements 
The results of the consensus process, with all questions and related statements, are summarized 
in Table 1. A strong consensus was reached for 16/20 statements and there was a lack of 
consensus for 3 statements. The jury decided that there was no scientific basis for voting on one 
statement (Statement #14 of the consensus). 
 
(I) Staging 
Rationale: Historically, LHON has been categorised into three distinct clinical groups: 
asymptomatic mutation carriers, patients with acute LHON (with disease duration of one year or 
less) and those with chronic LHON (with disease duration of more than one year) (9, 11). More 
recently, the assessment by OCT of the different stages of LHON (10, 22), in conjunction with the 
natural history (6, 8), and established visual parameters, such as best-corrected visual acuity and 
visual fields, have provided new insights that have led to the sub-classification of the acute stage 
into “subacute” and “dynamic” stages (Statement #1 of the consensus). Furthermore, other 
phenotypic groups have been proposed, namely, childhood- and late-onset LHON (23, 24), and the 
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contribution of anatomic (25), environmental (26-30) and hormonal factors (31) have emerged as 
potential disease modifiers. 
 
Question 1: How would you describe the different clinical stages of LHON? 
  
Clinical stages of LHON can be defined as follows, according to time from onset and clinical 
investigations: 
 0. Asymptomatic (mutation carriers) 
 1. Subacute (<6 months from onset) 
 2. Dynamic (6-12 months) 
 3. Chronic (>12 months) 
The following clinical variants can be also considered: 
1. Slowly progressive, defined according to patients’ characteristics independently from 
time since disease onset 
 2. Childhood disease, i.e. onset in a patient <12 years old 
 3. Late onset, i.e. onset in a patient >45 years old 
NB.  The jury emphasized that for the clinical diagnosis the following clinical investigations were 
important: visual acuity, colour vision, fundus examination, visual field perimetry, and OCT 
imaging. The participants also noted that for childhood disease, optic nerve head size was 
important. For late-onset LHON cases, the participants also felt that it was important to consider 
toxic exposure (smoking, drinking and environmental factors) and hormonal factors (oestrogens). 
To the statement, there was strong consensus. 
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(II) Diagnosis and prognosis 
Rationale:  
The diagnosis of LHON has been greatly improved by the availability of genetic testing (32). 
However, LHON remains a clinical diagnosis with easily recognizable classical features and disease 
evolution (4,5), which is corroborated by the maternal inheritance of the disease (33) when there 
is a family history, leading to Statement #2. 
3) Question 2: Are there any clinical characteristics, algorithms or investigations to reach a 
rapid diagnosis of LHON? 
Diagnosis of LHON can be usually made based on patient and family clinical history as well as 
baseline investigations including a formal neuro-ophthalmological examination and mtDNA 
genetic testing 
NB There was a strong consensus  
 Rationale: Despite the greatly improved recognition of LHON, there can still be 
considerable diagnostic delay that is compounded by variability in the initial findings and 
misinterpretation of the clinical picture, in particular with optic neuritis (34,35) or toxic optic 
neuropathy (36), thus a differential diagnosis remains an important point to consider, as remarked 
in Statements #3 and #4. 
4) Question 3:   Typically, how long does it take from symptom onset to confirmation of 
diagnosis? 
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“It can take months to reach a confirmed diagnosis” 
NB There was a strong consensus  
5) Question 4:   What are the main differential diagnoses? 
- Other optic neuropathies especially optic neuritis (neuromyelitis optica), toxic, 
metabolic and compressive optic neuropathies 
- Maculopathies 
- Non organic visual loss (not a diagnosis of exclusion) 
If further extraocular features are present, consider LHON ‘Plus’, including LHON/MS-like variant 
Consider performing appropriate investigations including brain MRI and laboratory studies 
NB There was strong consensus  
Rationale: Multiple reports on large LHON cohorts from different countries have defined some 
prognostic factors, which may impact the clinical course (23, 25, 37-39) and possibly the 
management of the disease, leading to Statement #5.  
6) Question 5:   How would you assess a patient’s prognosis? Does this impact on your 
management? 
In LHON, positive prognostic factors are: 
  Younger age 
  Type of mutation (14484/ND6) 
However, prognostic factors do not affect management 
NB There was a strong consensus  
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(III) Therapeutic management 
Rationale: The standard clinical evaluation of LHON patients includes visual acuity and visual 
fields. OCT studies have proved a valuable tool in evaluating the clinical course of the disease (6, 8, 
10, 22). These considerations lead to Statement #6. 
7) Question 6: Before initiating ANY treatment, what baseline assessments do you usually 
perform? 
The following examinations should be performed before starting any treatment:  
• Visual acuity (ETDRS charts) 
• Automated visual field test 
• OCT  (optic nerve head and RNFL analysis, and macular ganglion cell analysis) 
NB There was a strong consensus 
 
Rationale: Idebenone has been used as treatment of patients with LHON since 1992 (40-43). A 
number of publications have recently evaluated the therapeutic benefit of idebenone in LHON, 
including a placebo-controlled randomised clinical trial of 85 patients treated for 24 weeks with a 
dosage of 900 mg/day (16, 19, 20) and a large retrospective case-series of 44 patients treated with 
variable doses of idebenone over a mean treatment duration of 41 months compared with 59 
untreated patients (17). Based on the available literature and the personal experience of the 
experts, Statements #7-16 were formulated to critically evaluate a number of issues, including 
inclusion criteria for treatment, dosage and duration of treatment, as well as follow-up evaluations 
for assessing a clinically relevant response to treatment.  
Formatted: Normal,  No bullets or numbering
Formatted: Normal
Formatted: English (United States)
Formatted: Normal
Formatted: Font: Bold, English (United States)
Carelli et al., Consensus on LHON 2016 14 
8) Question 7: In subacute/dynamic (<6 months, 6-12 months) patients, at which stage of 
disease would you ideally start 900 mg/day treatment? 
“Idebenone should be started as soon as possible at 900 mg/day in patients with disease  
less than one year” 
NB There was a strong consensus with one participant in partial disagreement 
9) Question 8: In chronic cases, do you consider treatment? 
There is not enough evidence to recommend treatment in chronic patients between 1 and 5 years 
(after the 2nd eye onset), and no evidence to recommend treatment in chronic patients > 5 years 
(after the 2nd eye onset) 
 NB There was a strong consensus but two participants disagreed 
Question 9: What is your suggested frequency of follow-up, would it differ by stage? 
The ideal frequency of follow-up is as follows:  
 Approximately every 3 months for subacute and dynamic cases 
 Approximately every 6 months for the 2nd year 
 Once a year thereafter 
NB There was a strong consensus 
 
Question 10: How would you define a clinically relevant response (recovery of vision) to 
treatment? 
Response should be defined according to: 
 Improvement of two lines of BCVA on ETDRS charts (or from off-chart to on-chart) 
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 Automated visual field test (MD) 
NB There was strong consensus with one participant in partial disagreement 
Question 11: How long would you treat at 900 mg/day in order to assess response? 
“In subacute/dynamic patients, treatment at 900 mg/day should be continued for at least one year 
in order to assess the start of therapeutic response or until a plateau in terms of improvement is 
reached” 
NB There was strong consensus 
Question 12: Once you have confirmed a favorable clinically relevant outcome, for how long 
after plateau would you continue treatment? 
“One year” 
NB There was strong consensus but two participants partially disagreed and one participant 
disagreed 
Question 13: If you treat a chronic patient for how long you would continue treatment? 
“One year” 
NB Consensus was not reached. Five participants did not vote. 
Question 14: For chronic patients once you have confirmed a favorable clinically relevant 
outcome, for how long after plateau would you continue treatment? 
“One year” 
NB Not voted due to lack of consensus on statement #13.  
Question 15: What assessments do you perform to evaluate response during maintenance 
phase? 
Carelli et al., Consensus on LHON 2016 16 
The following examinations should be performed to assess response during maintenance phase:  
 Visual acuity 
 Automated visual field test 
NB There was strong consensus.  
Question 16: Do you consider a maintenance dose also for non-responders? 
“In non-responders, the maintenance dose can be 300 mg/day” 
NB There was strong disagreement with one participant in agreement 
 
(IV) Screening of family members 
Rationale: The provision of genetic testing (32) of the proband’s maternal lineage poses a number 
of ethical and economical issues, which led to Statement #17.   
Question 17: Is it necessary to perform genetic screening for LHON mutation in all maternally-
related family members? 
“No” 
NB There was a strong consensus 
Rationale: Similarly, the clinical evaluation and prophylactic treatment of unaffected LHON 
mutation carriers is a particularly relevant issue (9, 10, 25-27, 29, 39, 44-47).  This point has been 
developed in Statements #18 and #19.  
Question 18: Should all maternally-related relatives be clinically screened? 
Yes 
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NB 11 participants disagreed that all maternally-related relatives should be screened. There was 
strong disagreement with two participants in agreement 
Question 19: Would you consider treating them? 
“Currently treatment is not recommended for relatives of a LHON patient, but lifestyle counseling is 
recommended” 
NB There was a strong consensus 
Rationale: There are a few proposed risk factors for disease conversion (25, 27, 29, 39, 48). 
However, a systematic validation of these factors translated into a scoring system predicting 
disease risk is still pending. This issue led to the final Statement #20.   
Question 20: Are you aware of any algorithm or predictive risk factors that could be used to 
assess risk of becoming symptomatic? 
Currently there is no clinical prognostic factor that can be used  
NB There was strong consensus with one participant in disagreement.  
The Jury unanimously endorsed the final version of all questions and statements (Table 1).  
  
 
Discussion 
There was strong consensus for 16 statements, whereas for 3 statements there was lack of 
consensus (#13,#16, and #18). For statements #8, #12 and #20 there was specific disagreement 
from two, one and one participants, respectively. Specifically, for statement #8 the two 
participants thought that there was sufficient evidence to justify the use of idebenone for chronic 
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cases. For statement #12, one participant thought that idebenone treatment could be continued 
for more than 1 year after plateau in patients who had shown a treatment response. For 
statement #20, one participant disagreed that there is no reliable predictive risk factor to assess 
risk of disease conversion in a LHON carrier.  
There was strong disagreement for statements #16 and #18. Eleven out of 13 participants 
fully disagreed that idebenone should be continued with a maintenance dose in non-responder 
patients.  Also, 11 out of 13 participants fully disagreed that it was necessary to clinically screen all 
maternal relatives including asymptomatic carriers.   
Statements #1 to #6 and #9 pertained to the diagnosis and work-up of patients who 
presented with LHON for which there was strong consensus. The group debated the historical 
staging (9,11) of the disease and introduced a new distinction. Based on the currently available 
published evidence (6,8), the first year of the disease can be subdivided into subacute (less than 6 
months) and dynamic (6-12 months) phases, based on both functional and structural changes.  
Visual acuity decreases throughout the subacute phase and then stabilizes at about 6 months.  
Congruently, the thinning of macular RGC layer measured by OCT is largely completed by 4 to 6 
months, highlighting the severe cell loss of the cells originating the papillomacualr bundle (8, 49).  
Conversely, RNFL thickness evaluated by OCT is characterized in the first 6 months by swelling, 
followed by progressive quadrant specific thinning (6).  Thus, the dynamic stage, 6 to 12 months 
after onset, is characterized by still ongoing changes in RNFL as opposed to a substantial stability 
of RGC loss in the macula (8) Visual field defects may still progress in this dynamic stage (50). 
Although the ideal therapeutic window for LHON remains unknown, it is possible that there is a 
greater potential for visual recovery in the subacute phase compared with the dynamic phase.    
Statements #7, #8 and #10-16 pertained to the use of idebenone in LHON. The group 
agreed with consensus that idebenone was indicated in subacute and dynamic patients at 900 
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mg/day dosage (16), starting the treatment as soon as possible (17). There was also consensus 
about the continuation of the treatment in responders, based on the established outcome 
measures of best-corrected visual acuity and visual fields, and the criteria for defining a clinically 
relevant response (17).  The group strongly disagreed with the use of Idebenone as a maintenance 
dose in non-responders who have received treatment for one year.  Concerning patients in the 
chronic stage (> 1 year), it was determined that there was not enough evidence to support 
treatment for those patients with disease duration of 1-5 years, and no evidence for treatment 
after 5 years of disease duration. As a consequence, there was no consensus on statement #13 
and the Jury unanimously agreed not to vote on statement #14. The group based its judgment 
strictly on the existing data on clinical administration of idebenone in patients, as derived from the 
published literature (14-20, 40-43) and the unpublished information publicly available at the EMA 
website, including the European public assessment report (EPAR; ema.europa.eu/Find 
medicine/Human medicines/European public assessment reports) and the summary of the opinion 
of the Committee for Orphan Medicinal Products for Raxone (ema.europa.eu/Find 
medicine/Human medicines/Rare disease designation). Preclinical research has also been 
considered, with specific studies in cells derived from LHON patients as well as in animal models 
(51-55), being aware that the effectiveness and mechanisms of action of idebenone are still 
debated by the scientific community.  
Statements #17-20 pertained to the proband’s maternally-related relatives and specifically 
unaffected carriers.  The group agreed that the unaffected mutation carriers did not require 
routine genetic or clinical investigations. However, as best practice with any genetic disease, 
genetic counseling is offered to the patient who has the right to refuse any wider family 
involvement. Furthermore, the group had a strong consensus that treatment is not recommended 
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for asymptomatic carriers and that there is currently no prognostic measure to predict disease 
conversion. 
 
 
Conclusions and relevance for clinical practice 
The diagnosis of LHON should be based on a careful history, the evaluation of key 
structural and functional visual parameters, and on a molecular confirmation of a pathogenic 
mtDNA mutation.  The management of LHON includes the offer of genetic counseling, informing 
the patient about potentially preventable lifestyle risk factors and, for subacute and dynamic 
cases, the use of idebenone at the currently approved dose.  Idebenone should be discontinued in 
non-responder patients and is currently not recommended in patients in the chronic stages of the 
disease.  These guidelines and recommendations are based on a consensus developed on the 
current state of the literature.  Further investigations and clinical trials are needed to lead to 
better disease-modifying treatments and to improve the management of patients with LHON.  
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